Abstract: The results of the HHS Web Site Customer Satisfaction Survey will be used to ensure that the content on the HHS Web sites meets visitor needs and expectations. The results will also determine if the site is easy to use and the content easy to understand.

ESTIMATED ANNUALIZED BURDEN TABLE

<table>
<thead>
<tr>
<th>Form</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden hours per response (in hrs.)</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survey .................................................................</td>
<td>48,000</td>
<td>1</td>
<td>12/60</td>
<td>9,600</td>
</tr>
</tbody>
</table>

Mary Forbes,  
Office of the Secretary, Paperwork Reduction Act Reports Clearance Officer.  
[FR Doc. 2011–8796 Filed 4–12–11; 8:45 am]
BILLING CODE 4150–25–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Recommendations on In Vitro Ocular Safety Testing Methods and Strategies and Routine Use of Topical Anesthetics, Systemic Analgesics, and Humane Endpoints for Ocular Safety Testing

AGENCY: National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH).

ACTION: Notice of availability.

SUMMARY: U.S. Federal agency responses to ICCVAM test method recommendations on alternative testing methods and strategies proposed to further reduce and refine the use of animals for assessing the ocular hazard potential of chemicals and products are now available. ICCVAM recommended a pain management procedure that should always be used to avoid pain and distress when it is determined necessary to conduct the rabbit eye test for regulatory safety purposes. ICCVAM also recommended the Cytosensor Microphysiometer (CM) test method as a screening test (1) to identify some types of substances that will not cause sufficient injury to require eye hazard labeling and (2) to identify some types of substances that may cause permanent or severe eye injuries. ICCVAM previously forwarded recommendations to Federal agencies and made these recommendations available to the public (75 FR 57027). In accordance with the ICCVAM Authorization Act of 2000 (42 U.S.C. 285l–3), agencies have notified ICCVAM in writing of their findings and ICCVAM is making these responses available to the public. Federal agency responses are available on the NICEATM–ICCVAM Web site at http://iccvam.niehs.nih.gov/methods/ocutox/Transmit-2010.htm. The ICCVAM recommendations are provided in ICCVAM test method evaluation reports that are available on the NICEATM–ICCVAM Web site at http://iccvam.niehs.nih.gov/methods/ocutox/Transmit-2010.htm. The ICCVAM recommendations are provided in ICCVAM test method evaluation reports that are available on the NICEATM–ICCVAM Web site at http://iccvam.niehs.nih.gov/methods/ocutox/Transmit-2010.htm. The ICCVAM recommendations are provided in ICCVAM test method evaluation reports that are available on the NICEATM–ICCVAM Web site at http://iccvam.niehs.nih.gov/methods/ocutox/Transmit-2010.htm.

FOR FURTHER INFORMATION CONTACT: Dr. William S. Stokes, Director, NICEATM, NIEHS, P.O. Box 12233, Mail Stop: K2–16, Research Triangle Park, NC 27709, (telephone) 919–541–2384, (fax) 919–541–0947, (e-mail) niceatm@niehs.nih.gov. Courier address: NICEATM, NIEHS, Room 2034, 530 Davis Drive, Morrisville, NC 27560.

SUPPLEMENTARY INFORMATION:

Background

The U.S. Environmental Protection Agency (EPA) requested that ICCVAM (1) evaluate the current validation status of the bovine corneal opacity and permeability (BCOP), hen’s egg test–chorioallantoic membrane (HET–CAM), isolated chicken eye (ICE), and isolated rabbit eye (IRE) test methods; (2) identify in vivo ocular toxicity reference data to support the validation of in vitro test methods; (3) explore ways of alleviating pain and distress from current in vivo ocular safety testing; and (4) review the state of the science and the availability of in vitro test methods for assessing mild or moderate ocular irritants. The highest priority activity, an evaluation of the BCOP, HET–CAM, ICE, and IRE test methods for their usefulness and limitations for identifying potential ocular corrosives and severe irritants, was completed in 2006 (NIH Publication No. 07–4517). Based on this evaluation, U.S. Federal agencies subsequently adopted the BCOP and ICE test methods in 2009 as international OECD Test Guidelines 437 and 438, respectively (OECD 2009a, OECD 2009b). The International Organization for Standardization (ISO) adopted the BCOP and ICE test methods as ISO Standard 10993–10 in 2010 (ISO 2010).

ICCVAM recently completed additional test method evaluations relevant to the original EPA nomination and a subsequent EPA request that ICCVAM evaluate a proposed in vitro testing strategy for identifying the ocular hazard potential of antimicrobial cleaning products. Information is provided about ICCVAM’s evaluation and the committee’s recommendations for the alternative testing methods and strategies proposed to further reduce and refine the use of animals for assessing the ocular hazard potential of chemicals and products in four ICCVAM Test Method Evaluation Reports: (1) Recommendations for Routine Use of Topical Anesthetics, Systemic Analgesics, and Humane Endpoints to Avoid or Minimize Pain and Distress in Ocular Safety Testing (NIH Publication No. 10–7514), (2) Current Validation Status of In Vitro Test Methods Proposed for Identifying Eye Injury Hazard Potential of Chemicals and Products (NIH Publication No. 10–7533), (3) Current Validation Status of a Proposed In Vitro Testing Strategy for U.S. Environmental Protection Agency Ocular Hazard Classification and Labeling of Antimicrobial Cleaning Products (NIH Publication No. 10–7513), and (4) Recommendation to Discontinue Use of the Low Volume Eye Test for Ocular Safety Testing (NIH Publication No. 10–7515).

Agency Responses to ICCVAM Recommendations

ICCVAM is an interagency committee composed of representatives from 15 Federal regulatory and research agencies that require, use, generate, or disseminate toxicological and safety testing information. ICCVAM conducts technical evaluations of new, revised, and alternative safety testing methods with regulatory applicability and promotes the scientific validation and regulatory acceptance of toxicological and safety testing methods that more accurately assess the safety and hazards of chemicals and products and that reduce, refine (decrease or eliminate pain and distress), or replace animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C. 285–3) established ICCVAM as a permanent interagency committee of the NIEHS under NICEATM. NICEATM administers ICCVAM, provides scientific and operational support for ICCVAM-related activities, and conducts independent validation studies to assess the usefulness and limitations of new, revised, and alternative test methods and strategies.

ICCVAM recommendations and agency responses are available at the public. Agency responses should include identification of relevant test methods for which the ICCVAM test method recommendations may be added or substituted and indicate any revisions or planned revisions to existing guidelines, guidelines, or regulations to be made in response to these recommendations.

ICCVAM agencies concurred with the test method recommendations for the in vitro ocular safety testing methods and strategies and support the routine use of topical anesthetics, systemic anesthetics, and humane endpoints for ocular safety testing. Several agencies also indicated that they would communicate the ICCVAM recommendations to stakeholders to encourage their appropriate use. Agency responses are available at http://iccvam.niehs.nih.gov/methods/ocutox/Transmit-2010.htm.

**Background Information on ICCVAM and NICEATM**

ICCVAM is an interagency committee composed of representatives from 15 Federal regulatory and research agencies that require, use, generate, or disseminate toxicological and safety testing information. ICCVAM conducts technical evaluations of new, revised, and alternative safety testing methods with regulatory applicability and promotes the scientific validation and regulatory acceptance of toxicological and safety testing methods that more accurately assess the safety and hazards of chemicals and products and that reduce, refine (decrease or eliminate pain and distress), or replace animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C. 285–3) established ICCVAM as a permanent interagency committee of the NIEHS under NICEATM. NICEATM administers ICCVAM, provides scientific and operational support for ICCVAM-related activities, and conducts independent validation studies to assess the usefulness and limitations of new, revised, and alternative test methods and strategies. NICEATM and ICCVAM work collaboratively to evaluate new and improved test methods and strategies applicable to the needs of U.S. Federal agencies. NICEATM and ICCVAM welcome the public nomination of new, revised, and alternative test methods and strategies for validation studies and technical evaluations. Additional information about ICCVAM and NICEATM can be found on the NICEATM–ICCVAM Web site (http://iccvam.niehs.nih.gov).

**References**


Dated: April 1, 2011.

John R. Bucher, Associate Director, National Toxicology Program.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Medicare & Medicaid Services**

[CM–7031–NC]

Announcement of Notice; Proposed Establishment of a Federally Funded Research and Development Center—First Notice

**AGENCY:** Centers for Medicare & Medicaid Services (CMS), Department of Health & Human Services (DHHS).

**ACTION:** Notice.

**SUMMARY:** This notice announces our intention to sponsor Federally Funded Research and Development Center (FFRDC) to facilitate the modernization of business processes and supporting systems and their operations. This is the first of three notices which must be published over a 90-day period in order to advise the public of the agency’s intention to sponsor an FFRDC issued under the authority of 48 CFR 35.017.

**DATES:** We must receive comments on or before July 5, 2011.

**ADDRESSES:** Comments on this notice must be mailed to the Centers for Medicare & Medicaid Services, Candice Savoy, Contracting Officer, 7500 Security Boulevard, Mailstop C2–01–10, Baltimore, MD 21244 or e-mail at Candice.Savoy@cms.hhs.gov.

**FOR FURTHER INFORMATION CONTACT:** Candice Savoy, (410) 786–7494.

**SUPPLEMENTARY INFORMATION:**

The Centers for Medicare & Medicaid Services (CMS), an operating division within the Department of Health and Human Services (DHHS), intends to sponsor a studies and analysis, Delivery System, Simulations, and Cost Modeling Federally Funded Research and Development Center (FFRDC) to facilitate the modernization of business processes and supporting systems and their operations. Some of the broad task areas that will be utilized include Strategic/Tactical Planning, Conceptual Planning, Design and Engineering Procurement Assistance, Organizational Planning, Research and Development,